Logo Logo
Switch Language to German

Zoellner, Anna-Katharina; Weiglein, Tobias; Hutter, Grit; Zimmermann, Yvonne; Cieplik, Hans Christian; Hess, G. and Dreyling, Martin (2016): Temsirolimus acts as additive with bendamustine in aggressive lymphoma. In: Annals of Hematology, Vol. 95, No. 3: pp. 403-407

Full text not available from 'Open Access LMU'.


The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal role in the control of cell proliferation, survival, and angiogenesis with multiple and frequent dysregulations of this pathway in human tumors. Temsirolimus is an intravenous drug, specifically inhibiting the mTOR pathway. Bendamustine is well known for its clinical activity in indolent non-Hodgkin-lymphoma (NHL) and has lately shown clinical activity in mantle cell lymphoma (MCL). Here, we present a case report of temsirolimus in combination with bendamustine and rituximab leading to a CR in a pretreated male. In addition, our in vitro data underlines the additive and synergistic efficacy in cell growth reduction of temsirolimus combined with bendamustine in MCL cell lines and in DLBCL cell lines. Furthermore, as an underlying mechanism of this additive, effects on cell cycle inhibition and apoptosis induction could be identified.

Actions (login required)

View Item View Item